Literature DB >> 17011202

Enhanced survival and regeneration of axotomized retinal neurons by repeated delivery of cell-permeable C3-like Rho antagonists.

J Bertrand1, A Di Polo, L McKerracher.   

Abstract

Inactivation of Rho GTPase with a single intraocular injection of Rho antagonists stimulates survival and regeneration of retinal ganglion cells (RGCs) after optic nerve injury. However, this effect is short-lived. Here we tested the impact of multiple injections of C3-like Rho antagonists on RGC viability and axon regeneration after optic nerve lesion. Our data show that both neuronal survival and axon regeneration were enhanced with repeated delivery of cell-permeable C3. We found an approximately 1.5-fold increase in RCG survival when additional Rho antagonist injections were performed after the first week from the time of lesion. In contrast, increased regeneration required early inactivation of Rho and injections performed in the second week did not further enhance regenerative outcome. These results reveal differences in the length of the therapeutic windows through which Rho inactivation acts on RGC survival or regeneration after axotomy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011202     DOI: 10.1016/j.nbd.2006.08.008

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  12 in total

1.  RhoA knockdown by cationic amphiphilic copolymer/siRhoA polyplexes enhances axonal regeneration in rat spinal cord injury model.

Authors:  So-Jung Gwak; Christian Macks; Da Un Jeong; Mark Kindy; Michael Lynn; Ken Webb; Jeoung Soo Lee
Journal:  Biomaterials       Date:  2017-01-03       Impact factor: 12.479

Review 2.  Novel bacterial ADP-ribosylating toxins: structure and function.

Authors:  Nathan C Simon; Klaus Aktories; Joseph T Barbieri
Journal:  Nat Rev Microbiol       Date:  2014-07-14       Impact factor: 60.633

3.  C3 transferase gene therapy for continuous conditional RhoA inhibition.

Authors:  Claire-Anne Gutekunst; Jack K Tung; Margaret E McDougal; Robert E Gross
Journal:  Neuroscience       Date:  2016-10-13       Impact factor: 3.590

4.  Dysregulation of Rac or Rho elicits death of motor neurons and activation of these GTPases is altered in the G93A mutant hSOD1 mouse model of amyotrophic lateral sclerosis.

Authors:  Trisha R Stankiewicz; Claudia Pena; Ron J Bouchard; Daniel A Linseman
Journal:  Neurobiol Dis       Date:  2020-01-10       Impact factor: 5.996

Review 5.  Therapeutic effects of Clostridium botulinum C3 exoenzyme.

Authors:  Ingo Just; Astrid Rohrbeck; Stefanie C Huelsenbeck; Markus Hoeltje
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-12-31       Impact factor: 3.000

Review 6.  Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.

Authors:  Ponugoti Vasantha Rao; Padmanabhan P Pattabiraman; Casey Kopczynski
Journal:  Exp Eye Res       Date:  2016-09-01       Impact factor: 3.467

Review 7.  Discovery of novel inhibitors for the treatment of glaucoma.

Authors:  Kishore Cholkar; Hoang M Trinh; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Discov       Date:  2015-01-09       Impact factor: 6.098

8.  Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury.

Authors:  Peter X Shaw; Alan Sang; Yan Wang; Daisy Ho; Christopher Douglas; Lara Dia; Jeffrey L Goldberg
Journal:  Exp Eye Res       Date:  2016-07-18       Impact factor: 3.467

9.  Development of a cell permeable competitive antagonist of RhoA and CRMP4 binding, TAT-C4RIP, to promote neurite outgrowth.

Authors:  Mohammad R Khazaei; Samuel Montcalm; Adriana Di Polo; Alyson E Fournier; Yves Durocher; Stephan Ong Tone
Journal:  J Mol Neurosci       Date:  2015-02       Impact factor: 3.444

10.  Rac1 selective activation improves retina ganglion cell survival and regeneration.

Authors:  Erika Lorenzetto; Michele Ettorre; Valeria Pontelli; Matteo Bolomini-Vittori; Silvia Bolognin; Simone Zorzan; Carlo Laudanna; Mario Buffelli
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.